Abatacept Treatment Does Not Preserve Renal Function in the Streptozocin-Induced Model of Diabetic Nephropathy

Area of Science:

• Nephrology
• Immunology
• Endocrinology

Background:

• Diabetic nephropathy (DN) is a severe diabetes complication and leading cause of end-stage renal disease.
• Current treatment options for DN are limited, necessitating novel therapeutic strategies.
• Previous research suggested CTLA4-Ig (abatacept) might ameliorate DN by blocking B7-1 signaling.

Purpose of the Study:

• To investigate if B7-1 signaling is a promising therapeutic target for diabetic nephropathy.
• To evaluate the efficacy of abatacept in a mouse model of DN.

Main Methods:

• Mice were injected with streptozotocin (STZ) to induce diabetes.
• STZ-induced diabetic mice were treated with abatacept.
• Renal function, diabetes progression, albuminuria, and gene expression were assessed.
• Kidney histology and immune cell infiltration were analyzed.

Main Results:

• Abatacept treatment did not alter diabetes progression, renal function, or albuminuria in STZ-induced diabetic mice.
• Mesangial expansion and fibrotic gene expression remained unchanged.
• While abatacept reduced CD4+ T cell accumulation in kidneys, CCL5 expression was increased.
• B7-1 expression on podocytes was previously found to be low.

Conclusions:

• The study does not support a role for abatacept in treating diabetic nephropathy.
• B7-1 signaling is unlikely to be a key driver of pathology in this STZ-induced DN model.
• Renal T cell inflammation may not be a primary factor in STZ-induced DN pathogenesis.